Asia Pacific prostate cancer market is expected to grow at a CAGR of 7.9% during the forecast period. As per the World Health Organization, Asia Pacific is the second largest region in terms of new cases of prostate cancer globally. In 2018, around 321,000 new cases of prostate cancer were registered in the region. China has the highest incidence in the region followed by Japan however Australia has a very high incidence rate of prostate cancer. The highest rates of prostate cancer are reported in Australia and New Zealand presumably due to prostate-specific antigen (PSA) screening is done widely in these regions. In Asia Pacific, prostate cancer incidence has been reported to vary from country to country.
There has been a consistent increase in the age-standardized incidence rates of prostate cancer in Asian countries over the last few decades, particularly in Singapore, China, Malaysia, and Japan. This has been reported to be due to changes in diet and other lifestyle factors in these countries. Moreover, the adoption of innovative technologies for the diagnosis of prostate cancer such as biomarkers and the adoption of personalized medicine for treatment is expected to provide a significant opportunity to the market.
Geographically, the market is divided into China, Japan, India and the Rest of Asia Pacific. China is expected to hold a major market share followed by Japan. Japan caters to a high geriatric population base due to which a significant market share to the region is anticipated during the forecast period. The companies which are contributing significantly in the market include Abbott Laboratories, AbbVie Products, LLC, Amgen Inc., Ferring Pharmaceuticals Inc., Johnson & Johnson, Siemens Healthcare AG, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. In the report, the analysis of the country is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to brings authenticity to the reports.
Secondary Sources Include
The report is intended for drug manufacturing companies, medical device manufacturing companies, contract manufacturers, government organizations, and venture capitalists for the comprehensive market analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Asia Pacific Prostate Cancer Market by Diagnostic Techniques
5.1.1. Prostate-Specific Antigen Test (PSA)
5.1.2. Digital Rectal Examination
5.1.3. Prostate Biopsy
5.1.4. Imaging Techniques
5.2. Asia Pacific Prostate Cancer Market by Therapeutics
5.2.1. Hormonal Therapy
5.2.2. Chemotherapy
5.2.3. Immunotherapy
5.2.4. Radiation Therapy
5.2.5. Targeted Therapy
5.2.6. Surgery
6. Regional Analysis
6.1. China
6.2. Japan
6.3. India
6.4. Rest of Asia Pacific
7. Company Profiles
7.1. Abbott Laboratories
7.2. AbbVie Products, LLC
7.3. Amgen Inc.
7.4. AstraZeneca PLC
7.5. Bayer AG
7.6. Bristol-Myers Squibb Co.
7.7. Endo Pharmaceuticals Inc.
7.8. Ferring Pharmaceuticals Inc.
7.9. GlaxoSmithKline PLC
7.10. Johnson & Johnson
7.11. Pfizer Inc.
7.12. Siemens Healthcare AG
1. ASIA PACIFIC PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2018-2025 ($ MILLION)
2. ASIA PACIFIC PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)
3. ASIA PACIFIC PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
1. ASIA PACIFIC PROSTATE CANCER MARKET SHARE BY DIAGNOSTIC TECHNIQUE, 2018 VS 2025 (%)
2. ASIA PACIFIC PROSTATE CANCER MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)
3. ASIA PACIFIC PROSTATE CANCER MARKET SHARE BY COUNTRY, 2018 VS 2025 (%)
4. CHINA PROSTATE CANCER MARKET SIZE, 2018-2025 ($ MILLION)
5. JAPAN PROSTATE CANCER MARKET SIZE, 2018-2025 ($ MILLION)
6. INDIA PROSTATE CANCER MARKET SIZE, 2018-2025 ($ MILLION)
7. REST OF ASIA PACIFIC CANCER MARKET SIZE, 2018-2025 ($ MILLION)